Moncef Slaoui

Last updated

Publications

Related Research Articles

GlaxoSmithKline British pharmaceutical company

GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth largest pharmaceutical company according to Forbes as of 2019, after Pfizer, Novartis, Roche, Sanofi, and Merck & Co. GSK is the tenth largest pharmaceutical company and #296 on the 2019 Fortune 500, ranked behind other pharmaceutical companies including China Resources, Johnson & Johnson, Roche, Sinopharm, Pfizer, Novartis, Bayer, Merck, and Sanofi.

Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines.

Cervarix is a vaccine against certain types of cancer-causing human papillomavirus (HPV).

Beecham Group Pharmaceutical company (1859–1989)

The Beecham Group plc was a British pharmaceutical company. It was once a constituent of the FTSE 100 Index. Beecham, after having merged with American pharmaceutical company SmithKline Beckman to become SmithKline Beecham, merged with Glaxo Wellcome to become GlaxoSmithKline (GSK). GSK still uses the Beechams brand name in the UK for its over-the-counter cold and flu relief products.

Lonza Group Swiss chemical and biotech company

Lonza Group is a Swiss multinational chemicals and biotechnology company, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including organic, fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical synthesis capabilities, detection systems and services for the bioscience sector.

Andrew Witty British business executive (born 1964)

Sir Andrew Philip Witty is a British business executive, who was the chief executive officer (CEO) of GlaxoSmithKline between 2008 and 2017. Witty was succeeded by Emma Walmsley on 1 April 2017. He formerly held the role of chancellor of the University of Nottingham.

Pandemrix

Pandemrix is an influenza vaccine for influenza pandemics, such as the 2009 flu pandemic. The vaccine was developed by GlaxoSmithKline (GSK) and patented in September 2006.

GlaxoSmithKline Pharmaceuticals Ltd is an Indian subsidiary of GlaxoSmithKline plc, one of the world's leading research based pharmaceutical and healthcare companies. It is one of the oldest pharmaceuticals companies in India. Its product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer and others.

CureVac German bio-pharmaceutical company

CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018.

Moderna American biotechnology company innovating on mRNA-based medicines

Moderna, Inc., is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on vaccine technologies based on messenger RNA (mRNA). Moderna's vaccine platform inserts synthetic nucleoside-modified messenger RNA (modRNA) into human cells using a coating of lipid nanoparticles. This mRNA then reprograms the cells to prompt immune responses. Moderna develops mRNA therapeutic vaccines that are delivered in lipid nanoparticles, using mRNA with pseudouridine nucleosides. Candidates are designed to have improved folding and translation efficiency via insertional mutagenesis.

Emma Walmsley British businesswoman

Dame Emma Natasha Walmsley is the chief executive officer (CEO) of GlaxoSmithKline. She succeeded Sir Andrew Witty, who retired in March 2017. Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. She grew up Barrow-in-Furness, Cumbria.

Galvani Bioelectronics is a Stevenage, United Kingdom-based bioelectronics R&D company.

Patrick Vallance British medical doctor

Sir Patrick John Thompson Vallance is a British physician, scientist, and clinical pharmacologist who has worked in both academia and industry. He has served as the Chief Scientific Adviser to the Government of the United Kingdom since 2018.

Paul-Peter Tak is an immunologist and academic specialising in the fields of rheumatology and immunology. In addition to academic research, he served as an executive of several pharmaceutical companies.

A respiratory syncytial virus vaccine is a vaccine which prevents infection by respiratory syncytial virus. No licensed vaccine against RSV exists at this time (2021), although there is at least one vaccine candidate currently in clinical trials.

Operation Warp Speed American public–private partnership designed to accelerate COVID-19 vaccine development

Operation Warp Speed (OWS) was a public–private partnership initiated by the United States government to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The first news report of Operation Warp Speed was on April 29, 2020, and the program was officially announced on May 15, 2020. It was headed by Moncef Slaoui from May 2020 to January 2021 and by David A. Kessler from January to February 2021. At the end of February 2021, Operation Warp Speed was transferred into the responsibilities of the White House COVID-19 Response Team.

Jason S. McLellan is a structural biologist, associate professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at The University of Texas at Austin who specializes in understanding the structure and function of viral proteins, including those of coronaviruses. His research focuses on applying structural information to the rational design of vaccines and other therapies for viruses, including SARS-CoV-2, the novel coronavirus that causes COVID-19. McLellan and his team collaborated with researchers at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center to design a stabilized version of the SARS-CoV-2 spike protein, which biotechnology company Moderna used as the basis for the vaccine mRNA-1273, the first COVID-19 vaccine candidate to enter phase I clinical trials in the U.S. At least three other vaccines use this modified spike protein: those from Pfizer and BioNTech; Johnson & Johnson and Janssen Pharmaceutica; and Novavax.

CoVLP COVID-19 vaccine candidate produced in a plant

CoVLP is a COVID-19 vaccine candidate developed by Medicago and GlaxoSmithKline (GSK). It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana.

History of COVID-19 vaccine development Scientific work to develop a vaccine for COVID-19

COVID-19's caused virus, SARS-CoV-2, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

Sanofi–GSK COVID-19 vaccine Vaccine candidate against COVID-19

The Sanofi–GSK COVID-19 vaccine code-named VAT00002 and VAT00008 is a COVID-19 vaccine candidate developed by Sanofi Pasteur and GSK.

References

  1. USExpired 8597656B2,Cabezon, Teresa Silva; Slaoui, Moncef Mohamed& Cohen, Josephet al.,"Process for the production of immunogenic compositions",published March 12, 2013,issued March 12, 2013, assigned to GlaxoSmithKline Biologicals SA
  2. Mullard, Asher (July 1, 2015). "Moncef Slaoui". Nature Reviews Drug Discovery. 14 (7): 452–453. doi: 10.1038/NRD4669 . PMID   26129795.Wikidata-logo.svg Wikidata ( Wikidata-Reasonator small logo.svg )
  3. 1 2 3 4 5 Sanger, David E.; Haberman, Maggie; Weiland, Noah (May 15, 2020). "Trump Vows Vaccine by End of Year, and Mobilizes Military to Help". The New York Times.
  4. Bouzdaini, Wissam El (May 14, 2020). "Moncef Slaoui chargé par le président américain de développer le vaccin contre le COVID-19". Maroc Hebdo (in French).
  5. 1 2 3 4 5 6 Sulla, Adama (May 17, 2020). "La face cachée du Marocain qui doit développer un vaccin contre la covid-19". Challenge (in French).
  6. 1 2 3 4 5 6 7 Chala, Siham; Slaoui, Moncref (April 24, 2020). "Rencontre Trait d'Union ON LINE – Moncef SLAOUI, Avril 2020". Groupe HEM (HEM Institut des Hautes Etudes de Management / HEM Business School) (in French).
  7. 1 2 Nazih, Ahlam (June 28, 2017). "Moncef Slaoui, l'as des vaccins". L'Économiste (in French).
  8. 1 2 3 4 5 6 7 8 9 10 11 "Board of Directors: Dr Moncef Slaoui Independent member of the Board of Directors of Lonza Group Ltd (April 2020 until May 2020)". Lonza Group Ltd. Retrieved May 19, 2020.
  9. Slaoui, Moncef Mohamed (1983). Etude de la diversité et de la sélection des répertoires idiotypiques dans le système immunitaire (in French). Brussels: Université libre de Bruxelles, Faculté des sciences. identifier: ulbcat.ulb.ac.be:537608
  10. "Fierté Nationale: Moncef Slaoui à la tête du projet américain d'élaboration d'un vaccin anti-covid 19". L'Opinion . May 14, 2020.
  11. 1 2 Hatim, Yahia (May 14, 2020). "Moncef Slaoui to Outstrip Algerian, US Experts in 'Operation Warp Speed'". Morocco World News .
  12. 1 2 3 "Dr Moncef Slaoui: Is This The Man Who Can Save the World from Ebola?". International Business Times . August 12, 2015.
  13. Gribben, Roland (February 7, 2006). "Saviour of Glaxo to step down". The Telegraph .
  14. 1 2 3 Silverman, Ed (August 1, 2016). "Q&A: Glaxo exec says bioelectronics venture with Verily is 'not science fiction'". STAT .
  15. Carroll, John (August 3, 2017). "10 years and $100M-plus later, GSK shutters a China R&D site during a major pipeline overhaul". Endpoint News.
  16. 1 2 3 Cancryn, Adam; Diamond, Dan (May 14, 2020). "Meet the big pharma vet in charge of Trump's vaccine strategy". Politico .
  17. Lorenzetti, Laura (July 24, 2015). "World's first malaria vaccine, from GlaxoSmithKline, wins approval from EU". Fortune .
  18. Famm, Kristoffer; Litt, Brian; Tracey, Kevin J.; Boyden, Edward S.; Slaoui, Moncef (April 10, 2013). "A jump-start for electroceuticals". Nature . 496 (7444): 159–161. doi: 10.1038/496159A . PMC   4179459 . PMID   23579662.Wikidata-logo.svg Wikidata ( Wikidata-Reasonator small logo.svg )
  19. Slaoui, Moncef (March 3, 2016). "Dr. Moncef Slaoui on Bioelectronics". GSK.
  20. LaPook, Jonathan; Collins, Francis; Slaoui, Moncef; Tracey, Kevin (June 28, 2015). "Aspen Ideas Festival Spotlight Health 2015: Biology and Electronics Come Together (Full Session)". Atlantic LIVE.
  21. Slaoui, Moncef (July 1, 2013). "It's Time to Further Incentivize Medical Innovation". Huffington Post .
  22. "Opening of the GSK Global Vaccines R&D Center in Rockville, MD". GlaxoSmithKline. December 15, 2016. Retrieved May 19, 2020.
  23. "Strengthening Rockville as a major player in global healthcare". GlaxoSmithKline . Retrieved May 19, 2020.
  24. "Dr Moncef Slaoui, sommité mondiale de la santé, en visite au Maroc". La Nouvelle Tribune (in French). May 9, 2017.
  25. "The Power List 2016: Moncef Slaoui". Texere Publishing Limited. 2016.
  26. Cotaga, Olga (June 14, 2016). "GlaxoSmithKline Vaccines Unit Chairman to Retire Next Year". The Wall Street Journal .
  27. "Moncef M. Slaoui, Ph.D. Joins Moderna's Board of Directors" (PDF). July 27, 2017. Archived from the original (PDF) on May 28, 2020. Retrieved January 29, 2021.
  28. Hirschler, Ben (September 19, 2017). "Former GSK CEO and ex-R&D boss move to biotech venture firms". Reuters .
  29. Jacobs, Jennifer; Armstrong, Drew (May 14, 2020). "Trump Taps Ex-Glaxo Official and General to Lead Vaccine Race". Bloomberg News .
  30. "White House names heads of 'warp speed' coronavirus vaccine effort". CNN . May 13, 2020.
  31. "Remarks by President Trump on Vaccine Development". whitehouse.gov . May 15, 2020. Retrieved May 16, 2020 via National Archives.
  32. Delaney, Robert (May 16, 2020). "Coronavirus: US vaccine tsar expresses optimism in 'a few hundred million doses' by end of the year". South China Morning Post .
  33. Montgomery, Blake (May 15, 2020). "Trump's Vaccine Czar Holds Millions in Stock Options at Company That Got Federal Funding for COVID-19 Work". Yahoo! News . Retrieved May 18, 2020.
  34. "Trump's new coronavirus vaccine czar owns $10 million in stock options in company developing vaccine". Salon. May 18, 2020. Retrieved May 18, 2020.
  35. 1 2 Johnson, Carolyn Y. (May 20, 2020). "Moderna's coronavirus vaccine shows encouraging early results". The Washington Post .
  36. Perrett, Connor (May 18, 2020). "Trump's newly appointed coronavirus czar Moncef Slaoui will divest his $10 million in stocks from the pharma company Moderna, after initially claiming there was no conflict of interest". www.msn.com. Retrieved May 18, 2020.
  37. Perrett, Connor (May 18, 2020). "Trump's newly appointed coronavirus czar Moncef Slaoui will divest his $10 million in stocks from the pharma company Moderna, after initially claiming there was no conflict of interest". Business Insider .
  38. 1 2 3 4 "Trump's Vaccine Chief Has Vast Ties to Drug Industry, Posing Possible Conflicts". The New York Times . May 20, 2020.
  39. Dunn, Andrew (June 9, 2020). "Trump's coronavirus vaccine czar just pulled out of a marquee biotech conference. It would have been his first public appearance since taking the 'Operation Warp Speed' job". Business Insider .
  40. "Head of US vaccine effort resigns at request of incoming Biden administration but will stay through transition". CNN. January 13, 2021.
  41. Mangan, Dan (March 24, 2021). "GSK fires Trump Covid vaccine chief Moncef Slaoui for 'substantiated' sexual harassment claims". CNBC.
  42. "Moncef Slaoui Departs Galvani Bioelectronics Board of Directors". GlaxoSmithKline plc. March 24, 2021.
  43. "Ex-Operation Warp Speed boss loses pharma job after sex harassment probe". March 24, 2021.
  44. "Trump selects Muslim American to find Covid-19 vaccine". Dawn . May 17, 2020.
  45. "Despite anti-immigrant stance, Trump taps Moroccan migrant for vaccine role". TRT World . May 19, 2020.
  46. 1 2 3 "182nd Commencement". Gettysburg College. May 21, 2017. Retrieved May 19, 2020.
  47. 1 2 "The World's 50 Greatest Leaders: 29: Moncef Slaoui". Fortune . 2016.
  48. "HBKU board member is head of US vaccine development project". Gulf Times . May 17, 2020.
  49. "GSK Global Vaccines Chairman Moncef Slaoui joins IAVI Board of Directors". International AIDS Vaccine Initiative. January 12, 2015. Retrieved May 21, 2020.
  50. "The Human Vaccines Project Welcomes Moncef Slaoui to its Board of Directors". Human Vaccines Project. March 22, 2018. Retrieved May 20, 2020.
  51. National Academies of Sciences, Engineering, and Medicine; Nicholson, Anna; Brown, Lisa; Snair, Justin (2018). Examining Challenges and Possible Strategies to Strengthen U.S. Health Security: Proceedings of a Workshop. Washington, DC: The National Academies Press. p. vii. doi:10.17226/24856. ISBN   978-0-309-46375-1. PMID   29048863.CS1 maint: multiple names: authors list (link)
  52. Stendahl, Max (August 9, 2017). "Former GSK exec resigns from Intellia board due to 'conflict'". Boston Business Journal .
  53. 1 2 "MRNA Company Profile & Executives – Moderna Inc". The Wall Street Journal. Retrieved May 18, 2020.
  54. "Moncef Slaoui". The Wall Street Journal . Retrieved May 16, 2020.
  55. "Moncef Slaoui PhD". Divide & Conquer. Retrieved May 21, 2020.
  56. "Divide & Conquer". Divide & Conquer LLC. Archived from the original on December 7, 2019.
  57. "Moncef M.Slaoui, Ph.D. Joins Moderna's Board of Directors" (PDF). Moderna, Inc. July 27, 2017.
  58. "Board: Moncef Slaoui, Ph.D." Artizan Biosciences, Inc. Retrieved May 18, 2020.
  59. "Moncef Slaoui, Ph.D., Scientific and Strategic Advisor". Brii Biosciences. Archived from the original on May 17, 2020. Retrieved May 18, 2020.
  60. "CEO Appointed at Clasado Biosciences". Clasado Biosciences. December 11, 2019. Retrieved May 19, 2020.
  61. "Health & Regulatory Affairs Committee". BIO. Retrieved May 18, 2020.
  62. Hollmer, Mark (February 7, 2012). "Moncef Slaoui – The 25 most influential people in biopharma today" . Retrieved May 21, 2020.
  63. "The Power List 2018 – Industry Influencers: Moncef Slaoui, Partner, Medicxi". The Medicine Maker. 2018.
  64. "Masiyiwa, Musk Included In New African Magazine's 100 Most Influential Africans 2020". December 8, 2020. Retrieved January 13, 2021.

Further reading

Moncef Slaoui
Emma Walmsley and Moncef Slaoui, December 2016.jpg
Slaoui with GlaxoSmithKline CEO Emma Walmsley (December 2016)
Head of Operation Warp Speed
In office
May 15, 2020 January 12, 2021